{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:21:26Z","timestamp":1792693286346,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.ijpharm.2006.01.048","type":"journal-article","created":{"date-parts":[[2006,3,24]],"date-time":"2006-03-24T12:42:37Z","timestamp":1143204157000},"page":"140-147","source":"Crossref","is-referenced-by-count":44,"title":["Improved targeting of antimony to the bone marrow of dogs using liposomes of reduced size"],"prefix":"10.1016","volume":"315","author":[{"given":"Dante A.","family":"Schettini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul R.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Demicheli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olguita G.F.","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria N.","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilene S.M.","family":"Michalick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Fr\u00e9zard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2006.01.048_bib1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0005-2760(81)90311-8","article-title":"Liposome disposition in vivo. III. Dose and vesicle-size effects","volume":"666","author":"Abra","year":"1981","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ijpharm.2006.01.048_bib2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/00034983.1994.11812879","article-title":"Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy","volume":"88","author":"Alvar","year":"1994","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib3","unstructured":"Alving, C.R., Steck, E.A., 1980. Liposome carriers in chemotherapy of leishmaniasis. US Patent 4,186,183."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib4","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/0024-3205(80)90207-6","article-title":"Liposomes in leishmaniasis: therapeutic effects of antimonial drugs, 8-aminoquinolines, and tetracyclines","volume":"26","author":"Alving","year":"1980","journal-title":"Life Sci."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0169-4758(86)90039-6","article-title":"Liposomes as drug carriers in leishmaniasis and malaria","volume":"2","author":"Alving","year":"1986","journal-title":"Parasitol. Today"},{"key":"10.1016\/j.ijpharm.2006.01.048_bib6","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.2042-7158.1986.tb04623.x","article-title":"Nonionic surfactant vesicles, niosomes, as a delivery system for the antileishmanial drug sodium stibogluconate","volume":"38","author":"Baillie","year":"1986","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.2042-7158.1989.tb06399.x","article-title":"Visceral leishmaniasis: drug carrier characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB\/c mice","volume":"41","author":"Carter","year":"1989","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib8","first-page":"1028","article-title":"Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog","volume":"45","author":"Chapman","year":"1984","journal-title":"Am. J. Vet. Res."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/10611869308996069","article-title":"The distribution of free and non-ionic vesicular sodium stibogluconate in the dog","volume":"1","author":"Collins","year":"1993","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib10","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/aoc.425","article-title":"Pentavalent organoantimonial derivatives: two simple and efficient synthethic methods for meglumine antimonate","volume":"17","author":"Demicheli","year":"2003","journal-title":"Appl. Organomet. Chem."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2174\/1567269053828819","article-title":"Pentavalent antimonials: from chemistry to the design of new drugs","volume":"2","author":"Demicheli","year":"2005","journal-title":"Drug Des. Rev. (Online)"},{"key":"10.1016\/j.ijpharm.2006.01.048_bib12","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1590\/S0100-879X2000000700016","article-title":"Novel methods for the encapsulation of meglumine antimoniate in liposomes","volume":"33","author":"Fr\u00e9zard","year":"2000","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib13","unstructured":"Fr\u00e9zard, F., Demicheli, C., Schettini, D.A., Ribeiro, R.R., Melo, M.N., Michalick, M.S.M., 2004. Processo para a prepara\u00e7\u00e3o de formula\u00e7\u00f5es farmac\u00eauticas do antimoniato de meglumina em lipossomas e uso das formula\u00e7\u00f5es farmac\u00eauticas em animais acometidos com leishmaniose visceral. Brazilian Patent PI0405489-0, 11 November (pending)."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib14","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1590\/S0100-40422005000300025","article-title":"Liposomes: physicochemical and pharmacological properties, applications in antimony-based chemotherapy","volume":"28","author":"Fr\u00e9zard","year":"2005","journal-title":"Quim. Nova"},{"key":"10.1016\/j.ijpharm.2006.01.048_bib15","doi-asserted-by":"crossref","first-page":"17931","DOI":"10.1016\/S0021-9258(19)84662-8","article-title":"Chylomicron metabolism","volume":"264","author":"Hussain","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib16","series-title":"Liposomes: From Biophysics to Therapeutics","first-page":"109","article-title":"Liposome pharmacokinetics","author":"Hwang","year":"1987"},{"key":"10.1016\/j.ijpharm.2006.01.048_bib17","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/nbt1184-979","article-title":"Dehydration\u2013rehydration vesicles: a simple method for high yield drug entrapment in liposomes","volume":"2","author":"Kirby","year":"1984","journal-title":"Biotechnology"},{"key":"10.1016\/j.ijpharm.2006.01.048_bib18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1086\/515085","article-title":"U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis","volume":"28","author":"Meyerhoff","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0169-409X(97)00131-2","article-title":"Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system\u2014the concept of tissue specificity","volume":"32","author":"Moghimi","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib20","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jac\/8.5.371","article-title":"Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes","volume":"8","author":"New","year":"1981","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib21","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1128\/AAC.47.9.2781-2787.2003","article-title":"Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals","volume":"47","author":"Nieto","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1006\/abbi.2000.2046","article-title":"Physicochemical evaluation of a stability-driven approach to drug entrapment in regular and in surface-modified liposomes","volume":"383","author":"Peer","year":"2000","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib23","unstructured":"Rao, L.S., 1986. Anti-leishmanial pharmaceutical formulation. US Patent 4,594,241."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib24","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1128\/AAC.42.5.1076","article-title":"Characterization of the antimonial antileishmanial agent meglumine antimonate (glucantime)","volume":"42","author":"Roberts","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib25","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/vr.144.10.262","article-title":"Diagnosis of canine leishmaniasis by a polymerase chain reaction technique","volume":"144","author":"Roura","year":"1999","journal-title":"Vet. Rec."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1590\/S0100-879X2003000200015","article-title":"Distribution of liposome-encapsulated antimony in dogs","volume":"36","author":"Schettini","year":"2003","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib27","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1590\/S0100-879X2005001200017","article-title":"Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate","volume":"38","author":"Schettini","year":"2005","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0304-4165(85)90174-6","article-title":"Tissue distribution of liposomes exhibiting long half-lives in the circulation after in vivo injection","volume":"839","author":"Senior","year":"1985","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ijpharm.2006.01.048_bib29","first-page":"252","article-title":"American Veterinary Medical Association Panel of Euthanasia","volume":"8","author":"Smith","year":"1986","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib30","first-page":"439","article-title":"Formulation kit for liposomal doxorubicin composed of lyophilized liposomes","volume":"23","author":"Stevens","year":"2003","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0003-2697(80)90269-9","article-title":"Colorimetric determination of phospholipid with ammonium ferrothiocyanate","volume":"104","author":"Stewart","year":"1980","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib32","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/vr.138.8.181","article-title":"Disposition of antimony after the administration of N-methylglucamine antimoniate to dogs","volume":"138","author":"Valladares","year":"1996","journal-title":"Vet. Rec."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.4269\/ajtmh.1997.57.403","article-title":"Pharmacokinetics of liposome-encapsulated meglumine antimoniate after intramuscular and subcutaneous administration in dogs","volume":"57","author":"Valladares","year":"1997","journal-title":"Am. J. Med. Hyg."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0304-4017(01)00389-2","article-title":"Long term improvement in the treatment of canine leishmaniosis using antimony liposomal formulation","volume":"97","author":"Valladares","year":"2001","journal-title":"Vet. Parasitol."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0011-2240(86)90050-7","article-title":"Inhibition of dehydration-induced fusion between liposomal membranes by carbohydrates as measured by fluorescence energy transfer","volume":"23","author":"Womersley","year":"1986","journal-title":"Cryobiology"},{"key":"10.1016\/j.ijpharm.2006.01.048_bib36","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0304-4157(92)90038-C","article-title":"Sterically stabilized liposomes","volume":"1113","author":"Woodle","year":"1992","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ijpharm.2006.01.048_bib37","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/(SICI)1099-081X(199610)17:7<589::AID-BDD976>3.0.CO;2-D","article-title":"Biopharmaceutical evaluation of the liposomes prepared by rehydration of freeze-dried empty liposomes (FDELs) with an aqueous solution of a drug","volume":"17","author":"Yachi","year":"1996","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ijpharm.2006.01.048_bib38","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF01117450","article-title":"Application of Akaike\u2032s information criterion in the evaluation of linear pharmacokinetic equations","volume":"6","author":"Yamaoka","year":"1978","journal-title":"J. Pharmacokinet. Biopharm."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517306001402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517306001402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,25]],"date-time":"2021-07-25T04:59:56Z","timestamp":1627189196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517306001402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":38,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0378517306001402"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2006.01.048","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}